How is Effient Doing

[Anonymous]

I interviewed for a job as a Daiichi Sales Rep a few years ago. At that time I was told that Daiichi would be lainching an epic drug called Effient(I think this was the name).

I didn't get the job, i believe, because I asked alot of questions regarding Plavix and wanted to really understand how this Effient would compare, was there any concern with bleed outs and managed care coverage.

I think the RD thought I was challenging him but I was really trying to get the truth and determine if this was a blocbuster drug.

Is it doing well? Just thinking that I may have missed out on a killer opportunity thats all.

Thanks

 

[Anonymous]

I interviewed for a job as a Daiichi Sales Rep a few years ago. At that time I was told that Daiichi would be lainching an epic drug called Effient(I think this was the name).

I didn't get the job, i believe, because I asked alot of questions regarding Plavix and wanted to really understand how this Effient would compare, was there any concern with bleed outs and managed care coverage.

I think the RD thought I was challenging him but I was really trying to get the truth and determine if this was a blocbuster drug.

Is it doing well? Just thinking that I may have missed out on a killer opportunity thats all.

Thanks

The problem is that you were asking for the truth. That is not a vocabulary in this company. Who was the rd.

 

[Anonymous]

I interviewed for a job as a Daiichi Sales Rep a few years ago. At that time I was told that Daiichi would be lainching an epic drug called Effient(I think this was the name).

I didn't get the job, i believe, because I asked alot of questions regarding Plavix and wanted to really understand how this Effient would compare, was there any concern with bleed outs and managed care coverage.

I think the RD thought I was challenging him but I was really trying to get the truth and determine if this was a blocbuster drug.

Is it doing well? Just thinking that I may have missed out on a killer opportunity thats all.

Thanks

You didn't miss a thing

 

[Anonymous]

I interviewed for a job as a Daiichi Sales Rep a few years ago. At that time I was told that Daiichi would be lainching an epic drug called Effient(I think this was the name).

I didn't get the job, i believe, because I asked alot of questions regarding Plavix and wanted to really understand how this Effient would compare, was there any concern with bleed outs and managed care coverage.

I think the RD thought I was challenging him but I was really trying to get the truth and determine if this was a blocbuster drug.

Is it doing well? Just thinking that I may have missed out on a killer opportunity thats all.

Thanks

The projections for this product was to be in the billions per year. Easily swiping a piece of the market away from Plavix. I am not positive but I think the drug is pulling in a far lower number (100-200 mil per) Well below expectations. The only advantage that DS and EL have is time.....time. DS was only projecting "best case scenerios"..... Consider it a blessing they did not choose you. But maybe in a couple years, you can jump on when Effient has made improvements and Plavix is out of the way.....But it will be off-patent and in this economy........

 

[Anonymous]

Be glad that you weren't chosen. I wasted 2.5 years of my life taking progress tests and reading learning modules on that godforsaken drug, all to have it yanked away from me and put solely in the hospital rep's hands.
Eli Lilly is in charge of Effient for North America, and they made the idiotic decision to price it 18% above Plavix which led to the predictable (nonexistent) 3rd party payer coverage.
Effient was and is a complete waste of time.

 

[Anonymous]

Be glad that you weren't chosen. I wasted 2.5 years of my life taking progress tests and reading learning modules on that godforsaken drug, all to have it yanked away from me and put solely in the hospital rep's hands.
Eli Lilly is in charge of Effient for North America, and they made the idiotic decision to price it 18% above Plavix which led to the predictable (nonexistent) 3rd party payer coverage.
Effient was and is a complete waste of time.

That is because Lilly bullies the dsi management team. It is a dsi product, but dsi has not decision rights. JG and his mobs are little girls when dealing with Lilly management, and it has no respect for the little Nip company run by Italian mobsters.

 

[Anonymous]

That is because Lilly bullies the dsi management team. It is a dsi product, but dsi has not decision rights. JG and his mobs are little girls when dealing with Lilly management, and it has no respect for the little Nip company run by Italian mobsters.

First of all to suggest that the DSI "Management Team" could do better without Lilly is just ignorance. DSI is incompetent at the top. Second to suggest DSI has a "Mangement Team" is stupidity. You could take the entire "team" and not come up with one original thought between them.

 

[Anonymous]

Effient will never be more than a moderate success at best, generic clopidogrel will kill the majority of this market.